cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
2 Minutes Read

Melt-to-Make Patented Gummy Base Technology Supports Scalable Cannabis Edibles Manufacturing 

FOR IMMEDIATE RELEASE

Cannabis / Nutraceuticals / Manufacturing / Patent / Gummies / Growth / Scaling

“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president at Melt-to-Make.

NORTHAMPTON, Mass. — February 20, 2026 — As the global cannabis edibles market continues to expand, manufacturers are facing growing pressure to deliver compliant, consistent, and scalable products. According to Fortune Business Insights, the cannabis edibles market is projected to exceed $55 billion by 2034, reflecting sustained double-digit compound annual growth.

The expanding market is increasing demand for manufacturing systems that reduce formulation variability while improving production efficiency. In response, many producers are adopting standardized formulation platforms to support reliable output across product lines, facilities, and geographic markets.

Melt-to-Make has introduced a patented gelatin and pectin gummy base technology designed to address persistent bottlenecks in large-batch edible production. The company’s shelf-stable semi-finished gummy base can be heated and infused with active ingredients before molding, helping manufacturers simplify workflows while improving repeatability.

By standardizing the gummy base, the Melt-to-Make system reduces common manufacturing challenges associated with traditional confectionery production, including inconsistent texture, lengthy research and development cycles, and batch failures during scale-up.

“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president of product development and research at Melt-to-Make. “When the formulation system itself is consistent and repeatable, manufacturers can concentrate on dosing precision and operational efficiency rather than troubleshooting structure and texture.”

Traditional gummy production often requires specialized confectionery equipment and advanced formulation expertise, particularly when working with pectin in vegan and heat-stable applications. Melt-to-Make’s semi-finished gummy base is designed to integrate into existing production workflows, giving manufacturers a more standardized substrate for predictable results.

As regulated cannabis markets in the United States and Europe continue implementing stricter quality control and labeling standards, consistency in edible production is becoming increasingly important for both regulatory compliance and long-term brand reliability.

Standardized ingredient systems are emerging as a practical solution for achieving repeatable performance in expanding markets. Melt-to-Make currently serves clients in more than 15 countries and provides technical documentation, formulation tools, and production support for manufacturers implementing the technology.

To learn more, visit www.melt-to-make.com.

About Melt-to-Make™

Founded in 2018 in Northampton, Massachusetts, by Sarah McLaughlin, Jake Goodyear, and Tim Van Epps, Melt-to-Make™ specializes in innovative gummy base systems designed to simplify large-batch gummy manufacturing. By offering professionally formulated gelatin and pectin bases that are approximately 90% complete, the company helps manufacturers produce gummies faster, more efficiently, and with greater consistency.

Melt-to-Make™ is committed to using all-natural ingredients and colors while supporting a wide range of consumer preferences, including vegan, gluten-free, and non-GMO options. The company serves more than 1,000 B2B customers across the United States and in 15 countries, offering comprehensive support that includes equipment lists, training videos, custom formulations, and on-site technical assistance.

For more information, visit www.melt-to-make.com or call 1-800-241-0341.

Media Contact

Proven Media
Kim Prince
Phone: 480-221-7995
Email: kim@provenmedia.com

news culture Brands

73 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Helius Therapeutics and University of Auckland Launch Phase 2 Cannabis Sleep Trial

Update Helius Therapeutics Enters Groundbreaking Cannabis Sleep Study Helius Therapeutics, a trailblazer in New Zealand's medicinal cannabis sector, is embarking on an exciting journey to explore the potential of cannabis as a sleep aid. The company has signed a pivotal supply agreement with the University of Auckland for a Phase 2 clinical trial, which aims to investigate the effectiveness of cannabis-derived medicine for patients struggling with chronic back pain and sleep disturbances. Understanding the CPS Trial's Importance Known as the CPS Trial (Cannabis, Pain, Sleep), this innovative study will unfold over seven months, with participation from prominent institutions including Tauranga Hospital and the University of Otago. Lead investigator Dr. Saad Anis, an experienced pain medicine physician, emphasized the urgent need for credible research, noting that over 20% of New Zealand adults endure chronic non-cancer pain, often accompanied by sleep issues. "Many patients express interest in cannabis-derived medicines, yet definitive evidence is scarce, making it a challenge for healthcare providers to recommend them with confidence," he remarked. The Mechanics of the Trial Participants will engage in a randomized, double-blind, placebo-controlled crossover study, taking the study medicine at bedtime for three months, followed by a placebo for an additional three months. To track the participants’ sleep quality, their sleep patterns will be monitored meticulously using wrist-worn devices. The primary outcome is assessed through the Insomnia Severity Index, complemented by measures of sleep patterns derived from actigraphy. The Significance of High-Quality Evidence The trial, supported by the University of Auckland and an Australian and New Zealand College of Anaesthetists novice investigator grant, aims to produce important data that could reshape the landscape of medicinal cannabis. "This independent study is a crucial step forward for the sector, potentially improving general practice prescriptions and enhancing trust in cannabis therapies," noted Helius Therapeutics CEO Zoë Reece. As the medicinal cannabis sector evolves, effective clinical trials like CPS are viewed as building blocks towards validating these therapies. Growing Demand and Future Prospects As per Health New Zealand's data, medicinal cannabis dispensings have skyrocketed from 4,875 in 2020 to an impressive 389,668 in 2025. This surge highlights the increasing demand for medicinal cannabis as awareness and acceptance grow. Helius Therapeutics is keenly aware of this potential, demonstrating dedication to ensuring reliable and high-quality cannabis products. With over 80 products meeting the rigorous standards of New Zealand's Medicinal Cannabis Scheme, the outlook remains buoyant. What’s Next for the CPS Trial? The results of this pioneering CPS Trial are expected to be published in early 2028, with anticipation high amongst both the medical community and patients alike. Continued research will not only empower practitioners with data but also open avenues for patients to access cannabis therapies that genuinely improve their quality of life. Join the Conversation As the debate around medicinal cannabis evolves, it is crucial for industry stakeholders and patients to stay informed and engaged. Trials like the CPS could redefine how cannabis is perceived and utilized in healthcare, leading to more informed decisions in medical practices. Let's keep sharing these impactful developments!

The Race for Affordable Medical Cannabis: UK vs Germany Pricing Trends

Update The Cannabis Market Race: UK vs Germany As the European medical cannabis landscape continues to evolve, UK and Germany stand as the two major players, each contributing to a diverse market for patients. Recent changes in pricing dynamics have stirred interest and led to shifts in purchasing behaviors, particularly for patients seeking affordable cannabis alternatives. This comparison highlights the developing landscape of both countries and points towards the implications of these trends for executive cannabis professionals. Price Trends Shifting Dramatically Previously characterized by high prices, Germany has witnessed a notable price decline for cannabis flower. As of April 2026, the average price dropped to €6.55 per gram, a striking decrease from nearly €10 per gram just a year prior. Such a change has largely been attributed to an influx of products flooding the market, enhancing competition among licensed producers and imports. In contrast, the UK has shown a much more stable pricing trend, with average flower prices set at €7.78 per gram. This divergence speaks volumes about the market maturation process in both countries. As the UK market remains mostly private, its smaller number of flower SKUs, at 683 compared to Germany’s 1,748, could be a critical factor fueling a moderately steady price range. Market Expansion and Product Diversity The expansion of the medical cannabis market in both regions points to a future filled with potential and opportunity. Germany’s explosion of products—over 1,748 flower SKUs—is a clear indicator of a rapidly developing sector, bringing accessibility to thousands of patients previously left in the dark. In 2026, as more patients opt to pay privately due to regulatory changes, the numbers supporting this growth speak volumes. Conversely, the UK’s product variety increased significantly, growing 2.4 times compared to last year. This burgeoning market indicates a consumer base eager for more options, and the challenge now lies with clinic operators to ensure product quality and consistency. Regulatory Changes Impacting Patients Importantly, the impending BStabG regulation which removed medical cannabis flower from reimbursement under statutory health insurance (GKV) in Germany symbolizes a critical juncture for patient care. Although the overall price per gram has not yet reacted to these changes, the shift could lead to a significant increase in privately paying patients, currently estimated at around 65,000. How this regulation evolves will likely redefine patient accessibility and market flow. What Lies Ahead for Executives in Cannabis For executive cannabis professionals, this comparison calls for reflection on market strategy and adjustment. A deep understanding of the trends softening flower prices in Germany and the steady nature of the UK market is crucial for harnessing future opportunities. By recognizing the drive behind these shifts, executives can strategically position their businesses, focusing on product development, competitive pricing, and adapting to tailored patient needs. Engage with your peers in these discussions and remain informed about ongoing regulatory changes, as they will play a pivotal role in shaping the medical cannabis landscape of tomorrow.

Hall of Flowers Week in NYC: A Cultural Revolution for Cannabis Enthusiasts

Update The Rise of Hall of Flowers: A Cultural Movement The Hall of Flowers event, which began modestly in California in 2018, has grown into an influential showcase for cannabis culture. As it makes its New York debut, the event promises to transcend the traditional boundaries of industry trade shows by incorporating vibrant public events. With the tagline of being a trade show that represents the culture it serves, Hall of Flowers has managed to capture the imagination of both industry insiders and the general public alike. What to Expect at Hall of Flowers Week This year's festivities, running from October 19-22, will not only fill Pier 36 but also spill throughout Manhattan and Brooklyn. The lineup includes a variety of events — from comedy showcases and art installations to educational panels, all aligned with cannabis culture. "A lot of us who built Hall of Flowers grew up around and love the plant," says co-founder Rama Mayo, signaling the deep-seated passion behind this initiative. Exclusive Events to Mark Your Calendar Among the highlights is a VIP Night hosted by Zig-Zag, which will take place at Torches dispensary. This event promises to engage attendees in an intimate setting featuring discussions led by cannabis journalists and industry veterans, enhancing connections within a blossoming community. Other notable events kick off the week with educational experiences such as David Bienenstock’s history of cannabis at Caveat. Attendees can immerse themselves in how cannabis has evolved over 10,000 years all while exploring networking opportunities. Unveiling Unique Exhibitors and Products Hall of Flowers showcases over 200 exhibitors, many of whom are bringing innovative products exclusive to this event. A highlight is Stone Road’s introduction of the first legal charas in New York, while Dabwoods merges cannabis with streetwear culture. The unique offerings aim not just to attract buyers but also to resonate with a crowd that values creativity and authenticity. Embracing Community and Culture The incorporation of public events is significant; it allows for a broader engagement with the cannabis culture. Exhibitors will also engage attendees in crafting a narrative about wellness, creativity, and the evolving landscape of cannabis use—from health benefits to the cultural significance of the plant. The Hall of Flowers serves as a reminder that cannabis has a rich history intertwined with creativity and community. Future Implications: Where is Cannabis Culture Headed? With events like Hall of Flowers gaining traction in key urban markets, it signals a robust future for cannabis culture and commerce. As the industry continues to evolve with emerging trends and products, the awareness and accessibility of cannabis are sure to expand, heightening public interest and understanding. For those involved in industry advocacy and education, Hall of Flowers Week serves as a fertile ground for innovation and cultural dialogue. This is not just about the products displayed, but also about community building and the cultural fabric that binds enthusiasts together. As New York embraces this event, it indicates a shift towards normalization and acceptance that could redefine societal perceptions moving forward.

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*